Jon Curwen

TL;DR: ZD6474 is a potent, p.o. active, low molecular weight inhibitor of kinase insert domain-containing receptor that demonstrates selectivity against a range of other tyrosine and serine-threonine kinases and translates into potent inhibition of vascular endothelial growth factor-A (VEGF)-stimulated endothelial cell proliferation in vitro.

TL;DR: The data obtained with AZD2171 are consistent with potent inhibition of VEGF signaling, angiogenesis, neovascular survival, and tumor growth.

TL;DR: A novel subseries of 4-anilinoquinazolines that possess basic side chains at the C-7 position of the quinazoline nucleus have been synthesized, and one of the compounds demonstrated highly significant, dose-dependent, antitumor activity in athymic mice.

TL;DR: AZD0530 is a potent inhibitor of tumor growth in a c-Src-transfected 3T3-fibroblast xenograft model in vivo and led to a significant increase in survival in a highly aggressive, orthotopic model of human pancreatic cancer when dosed orally once daily.

TL;DR: Inhibition of growth of human tumors in athymic mice has also been demonstrated: compound 34 inhibited the growth of established Calu-6 lung carcinoma xenograft by 75% (P < 0.001, one tailed t-test) following daily oral administration of 100 mg/kg for 21 days.